Welcome to our dedicated page for Nektar Therapeutics SEC filings (Ticker: NKTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nektar Therapeutics filings document the regulatory record of a Delaware clinical-stage biotechnology issuer with common stock listed on the Nasdaq Capital Market under NKTR. The company's 8-K reports cover financial results, Regulation FD clinical disclosures for rezpegaldesleukin, material definitive agreements, underwriting arrangements, at-the-market equity distribution mechanics, and shelf-registration-related offerings.
Proxy materials describe annual meeting matters, director elections, equity incentive plan authorization, auditor ratification, executive compensation votes, and governance procedures. Nektar's filing record also reflects capital-structure disclosures for common stock and pre-funded warrants, clinical-stage pipeline risks, research and development funding needs, and public-company controls tied to its immunology drug development business.
NKTR files a Section 144 notice to sell 180 common shares related to restricted stock vesting dated 02/13/2026. The filing lists a proposed sale of 180 shares by Fidelity Brokerage Services LLC.
The excerpt also records prior sales by Jonathan Zalevsky: 1,157 shares sold on 11/25/2025 and 3,867 shares sold on 01/20/2026, with corresponding dollar amounts shown in the table.
G1 Execution Services, Susquehanna Portfolio Strategies, and Susquehanna Securities filed Amendment No. 1 to a Schedule 13G reporting beneficial ownership of 809,967 shares of Nektar Therapeutics common stock, equal to 4.0% of the class.
The filing is based on 20,341,589 shares outstanding as of November 10, 2025, as disclosed in the company’s Form S-3ASR. Susquehanna Securities’ position includes options to buy 410,600 shares. The firms state the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Nektar.
Nektar Therapeutics is raising new capital through an upsized underwritten public offering of common stock and pre-funded warrants. The company agreed to sell 6,603,449 common shares at $58.00 each and 293,103 pre-funded warrants at $57.9999 each, with underwriters also exercising a 30-day option to buy an additional 1,034,482 common shares at the public price, all before underwriting discounts and commissions.
The transaction is expected to generate gross proceeds of about $400 million and is scheduled to close on February 13, 2026, subject to customary conditions. Nektar plans to use the net proceeds for general corporate purposes, including research and development, Phase 3 trials for rezpegaldesleukin, clinical development, and manufacturing costs to advance its drug pipeline.
Nektar Therapeutics is offering 6,603,449 shares of common stock and pre-funded warrants to purchase up to 293,103 shares, at $58.00 per share (or $57.9999 per pre-funded warrant), for estimated net proceeds of about $375.6 million, or $432.0 million if the underwriters fully exercise their option for 1,034,482 additional shares.
The company plans to use the cash, together with existing funds, for general corporate purposes, including research, clinical development and manufacturing, notably Phase 3 trials for its autoimmune drug candidate rezpegaldesleukin. Nektar reported preliminary cash and marketable securities of approximately $229.1 million as of January 31, 2026.
Recent Phase 2b REZOLVE‑AD data in atopic dermatitis showed sustained efficacy through 52 weeks and a well‑tolerated safety profile, and Nektar has aligned with the FDA on two Phase 3 registrational trials starting in the second quarter of 2026. The company highlights significant dilution to new investors versus its September 30, 2025 net tangible book value per share.
Nektar Therapeutics is offering $300,000,000 of common stock and pre-funded warrants in a primary financing to support its drug development programs. Investors may buy common shares or, in lieu of shares, pre-funded warrants exercisable for one share at an exercise price of $0.0001 per share.
The company is a clinical-stage immunotherapy developer with lead autoimmune candidate rezpegaldesleukin and oncology asset NKTR-255. It recently reported positive 52‑week Phase 2b REZOLVE‑AD data in atopic dermatitis, showing sustained EASI‑75, EASI‑90 and itch responses with monthly and quarterly dosing.
Nektar plans Phase 3 trials of rezpegaldesleukin starting in the second quarter of 2026. It estimates approximately $229.1 million in cash and marketable securities as of January 31, 2026, after also raising about $39.4 million via at‑the‑market sales of 673,725 shares at a weighted average price of $58.55.
Nektar Therapeutics is offering $300,000,000 of common stock and pre-funded warrants in a primary financing to support its drug development programs. Investors may buy common shares or, in lieu of shares, pre-funded warrants exercisable for one share at an exercise price of $0.0001 per share.
The company is a clinical-stage immunotherapy developer with lead autoimmune candidate rezpegaldesleukin and oncology asset NKTR-255. It recently reported positive 52‑week Phase 2b REZOLVE‑AD data in atopic dermatitis, showing sustained EASI‑75, EASI‑90 and itch responses with monthly and quarterly dosing.
Nektar plans Phase 3 trials of rezpegaldesleukin starting in the second quarter of 2026. It estimates approximately $229.1 million in cash and marketable securities as of January 31, 2026, after also raising about $39.4 million via at‑the‑market sales of 673,725 shares at a weighted average price of $58.55.
Nektar Therapeutics provided a liquidity update, stating it had approximately $229.1 million in cash and investments in marketable securities as of January 31, 2026. This figure is described as an estimate based solely on information available at the time of the announcement.
The company notes that this cash and investment balance is not a comprehensive statement of its operating results or full financial position for that date. The information was furnished under a Regulation FD disclosure item and is not deemed filed for liability purposes or automatically incorporated into other securities filings.
Nektar Therapeutics provided a liquidity update, stating it had approximately $229.1 million in cash and investments in marketable securities as of January 31, 2026. This figure is described as an estimate based solely on information available at the time of the announcement.
The company notes that this cash and investment balance is not a comprehensive statement of its operating results or full financial position for that date. The information was furnished under a Regulation FD disclosure item and is not deemed filed for liability purposes or automatically incorporated into other securities filings.
Nektar Therapeutics reported new 36-week maintenance data from its 52-week Phase 2b REZOLVE-AD trial of rezpegaldesleukin in moderate-to-severe atopic dermatitis. Among re-randomized responders, both monthly (Q4W) and quarterly (Q12W) dosing maintained high response rates, including up to 83% maintaining EASI-75 and strong vIGA-AD and itch responses.
A meaningful share of patients also achieved new or deeper responses by Week 52, including increases in EASI-90 and EASI-100 rates, indicating continued improvement with longer treatment. The safety profile over 52 weeks remained consistent with induction, with low discontinuations, mainly mild injection site reactions, and no new safety concerns.
Nektar held an End of Phase 2 meeting with the FDA and reached alignment on a 24 µg/kg Q2W induction dose and co-primary endpoints for two planned Phase 3 registrational trials, which will include a 36-week maintenance period with Q4W and Q12W regimens. The company plans to start Phase 3 in the second quarter of 2026 and is targeting a BLA filing in 2029 based on its broader development plan.
Nektar Therapeutics reported new 36-week maintenance data from its 52-week Phase 2b REZOLVE-AD trial of rezpegaldesleukin in moderate-to-severe atopic dermatitis. Among re-randomized responders, both monthly (Q4W) and quarterly (Q12W) dosing maintained high response rates, including up to 83% maintaining EASI-75 and strong vIGA-AD and itch responses.
A meaningful share of patients also achieved new or deeper responses by Week 52, including increases in EASI-90 and EASI-100 rates, indicating continued improvement with longer treatment. The safety profile over 52 weeks remained consistent with induction, with low discontinuations, mainly mild injection site reactions, and no new safety concerns.
Nektar held an End of Phase 2 meeting with the FDA and reached alignment on a 24 µg/kg Q2W induction dose and co-primary endpoints for two planned Phase 3 registrational trials, which will include a 36-week maintenance period with Q4W and Q12W regimens. The company plans to start Phase 3 in the second quarter of 2026 and is targeting a BLA filing in 2029 based on its broader development plan.
The Vanguard Group reports beneficial ownership of 1,027,089 shares of Nektar Therapeutics common stock, representing 5.04% of the class as of December 31, 2025. Vanguard reports no sole voting or dispositive power, with all 1,027,089 shares held with shared dispositive power and 143,138 shares with shared voting power.
The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Nektar. Vanguard notes an internal realignment effective January 12, 2026, after which certain subsidiaries are expected to report beneficial ownership separately.
Nektar Therapeutics is entering a quiet period starting January 27, 2026 as it prepares analyses of 36-week maintenance data from its Phase 2b REZOLVE-AD study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis. During this time, the company plans to limit public communications about these data.
The quiet period is described as consistent with Nektar’s prior practices for its REZOLVE studies and planned data disclosures. The next planned investor communication is expected in February 2026, when the company plans to present the maintenance data.
Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky reported a planned stock sale under a pre-arranged Rule 10b5-1 trading plan. On January 20, 2026, he sold 3,867 shares of Nektar common stock at a weighted average price of $35.67 per share, through multiple trades within a price range of $35.17 to $36.23. After this transaction, he directly held 21,354 shares of Nektar common stock.